A phase II study of bendamustine chemotherapy as second-line treatment in metastatic uveal melanoma

Melanoma Research

Volumn 14, Issue 6, 2004, Pages 439-442

  Schmidt Hieber, Martin ^a   Schmittel, Alexander ^a   Thiel, Eckhard ^a   Keilholz, Ulrich ^a,b  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^b FREIE UNIVERSITÄT BERLIN   (Germany)

Author keywords

Bendamustine; Phase II trial; Uveal melanoma

Indexed keywords

ANTIHISTAMINIC AGENT; BENDAMUSTINE; CIMETIDINE; DEXAMETHASONE; NUCLEOSIDE DERIVATIVE; RANITIDINE; SEROTONIN 3 ANTAGONIST;

ADULT; AGED; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ACTIVITY; DRUG EFFICACY; DRUG FEVER; FEMALE; HUMAN; LEUKOPENIA; MALE; METASTASIS; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; THROMBOCYTOPENIA; UVEA MELANOMA;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; NITROGEN MUSTARD COMPOUNDS; SALVAGE THERAPY; SKIN NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME; UVEAL NEOPLASMS;

EID: 13544268642     PISSN: 09608931     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008390-200412000-00001     Document Type: Article

References (32)

1. Cutler SJ, Young JL, Connelly RR. Third national cancer survey: incidence data. Natl Cancer Inst Monogr 1975; 41:1-454.
2. Liu CC, Kou HK, Tsai MH, Su CC, Kao ML, Chen YJ, et al. Choroidal masses: a fourteen-year analysis. Chang Gung Med J 2001; 24:502-511.
3. Diener-West M, Hawkins BS, Markowitz JA, Schachat AP. A review of mortality from choroidal melanoma. II. A meta-analysis of 5-year mortality rates following enucleation, 1966 through 1988. Arch Ophthalmol 1992; 110:245-250.
4. Pyrhonen S. The treatment of metastatic uveal melanoma. Eur J Cancer 1998; 34:S27-S30.
5. Schmittel A, Bechrakis NE, Scheibenbogen C, Mailaender V, Mutlu D, Foerster MH, et al. Prognostic factors for development of metastatic disease in ocular melanoma: 5 years follow-up of 271 patients. Proc ASCO 2003; 22:2860.
6. Collaborative Ocular Melanoma Study (COMS). Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol 2001; 119:670-676.
7. Jäckel A, Bock M, Deichmann M, Waldmann V, Näher H. Therapy of metastatic malignant uveal melanoma. Hautarzt 2001; 52:98-103.
8. Becker JC, Terheyden P, Kämpgen E, Wagner S, Neumann C, Schadendorf D, et al. Treatment of disseminated ocular melanoma with sequential fotemustine, interferon alpha, and interleukin 2. Br J Cancer 2002; 87: 840-845.
9. Eskelin S, Pyrhonen S, Hahka-Kemppinen M, Tuomaala S, Kivela T. A prognostic model and staging for metastatic uveal melanoma. Cancer 2003; 97:465-475.
10. Salmon RJ, Levy C, Plancher C, Dorval T, Desjardins L, Leyvraz S, et al. Treatment of liver metastases from uveal melanoma by combined surgery-chemotherapy. Eur J Surg Oncol 1998; 24:127-130.
11. Bedikian AY, Papadopoulos N, Plager C, Eton O, Ring S. Phase II evaluation of temozolomide in metastatic choroidal melanoma. Melanoma Res 2003; 13:303-306.
12. Woll E, Bedikian A, Legha SS. Uveal melanoma: natural history and treatment options for metastatic disease. Melanoma Res 1999; 9:575-581.
13. Pyrhonen S, Hahka-Kemppinen M, Muhonen T, Nikkanen V, Eskelin S, Summanen P, et al. Chemoimmunotherapy with bleomycin, vincristine, lomustine, dacarbazine (BOLD), and human leukocyte interferon for metastatic uveal melanoma. Cancer 2002; 95:2366-2372.
14. Kivela T, Suciu S, Hansson J, Kruit WH, Vuoristo MS, Kloke O, et al. Bleomycin, vincristine, lomustine and dacarbazine (BOLD) in combination with recombinant interferon alpha-2b for metastatic uveal melanoma. Eur J Cancer 2003; 39:1115-1120.
15. Leyvraz S, Spataro V, Bauer J, Pampallona S, Salmon R, Dorval T, et al. Treatment of ocular melanoma metastatic to the liver by hepatic arterial chemotherapy. J Clin Oncol 1997; 15:2589-2595.
16. Egerer G, Lehnert T, Max R, Naeher H, Keilholz U, Ho AD. Pilot study of hepatic intraarterial fotemustine chemotherapy for liver metastases from uveal melanoma: a single-center experience with seven patients. Int J Clin Oncol 2001; 6:25-28.
17. Pföhler C, Cree IA, Ugurel S, Kuwert C, Haass N, Neuber K, et al. Treosulfan and gemcitabine in metastatic uveal melanoma patients: results of a multicenter feasibility study. Anticancer Drugs 2003; 14:337-340.
18. Neale MH, Myatt NE, Khouty GG, Weaver P, Lamont A, Hungerford JL, et al. Comparison of the ex vivo chemosensitivity of uveal and cutaneous melanoma. Melanoma Res 2001; 11:601-609.
19. Keilholz U, Schuster R, Schmittel A, Bechrakis N, Siehl J, Foerster MH, et al. A clinical phase 1 trial of gemcitabine and treosulfan (GeT) in uveal melanoma and other solid tumors. Eur J Cancer 2004; 40:2047-2052.
20. Agarwala SS, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman E, et al. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol 2002; 20:125-133.
21. Bechrakis NE, Scheibenbogen C, Schmittel A, Servetopoulou F, Foerster MH, Keilholz U. Choroid melanoma. Adjuvant therapy in high risk patients and new therapy approaches in the metastatic stage. Ophthalmologie 2002; 99:333-337.
22. Diehl V, Cheson BD. Bendamustine in the treatment of hematologic malignancies. Introduction. Semin Oncol 2002; 29:S1-S3.
23. Reck M, Haering B, Koschel G, Kaukel E, von Pawel J, Gatzemeier U. Chemotherapy of advanced non-small-cell and small-cell bronchial carcinoma with bendamustine - a phase II study. Pneumologie 1998; 52:570-573.
24. Schöffski P, Seeland G, Engel H, Grunwald V, Paul H, Merkle K, et al. Weekly administration of bendamustine: a phase I study in patients with advanced progressive solid tumours. Ann Oncol 2000; 11:729-734.
25. Balfour JA, Goa KL. Bendamustine. Drugs 2001 ; 61:631-638.
26. Preiss R, Sohr R, Matthias M, Brockmann B, Huller H. The pharmacokinetics of bendamustine (Cytostasane) in humans. Pharmazie 1985; 40: 782-784.
27. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, et al. New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92:205-216.
28. Simon R. Optimal two-stage designs for phase II clinical trials. Control Clin Trials 1989; 10:1-10.
29. Bedikian AY, Kantarjian H, Young SE, Bodey GP. Prognosis in metastatic choroidal melanoma. South Med J 1981; 74:574-577.
30. Keilholz U, Martus P, Punt CJ, Kruit W, Mooser G, Schadendorf D, et al. Prognostic factors for survival and factors associated with long-term remission in patients with advanced melanoma receiving cytokine-based treatments: second analysis of a randomised EORTC Melanoma Group trial comparing interferon-alpha2a (IFNalpha) and interleukin 2 (IL-2) with or without cisplatin. Eur J Cancer 2002; 38:1501-1511.
31. Dunne BM, McNamara M, Clynes M, Shering SG, Larkin AM, Moran E, et al. MDR1 expression is associated with adverse survival in melanoma of the uveal tract. Hum Pathol 1998; 29:594-598.
32. Van der Pol JP, Blom DJ, Flens MJ, Luyten GP, de Waard-Siebinga I, Koornneef L, et al. Multidrug resistance-related proteins in primary choroidal melanomas and in vitro cell lines. Invest Ophthalmol Vis Sci 1997; 38:2523-2530.